Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
106.2 ^USD	-2.45%		+4.10%	+6.77%

Apr. 24	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
Apr. 24	Moderna to Collaborate With OpenAI to Launch New Generation of Medicines	MT

Moderna : EMA Is Set To Consider Next Month Whether To Approve Vaccine Candidates Developed By Pfizer/Biontech, Moderna - FT

November 29, 2020 at 02:26 pm EST

Nov 29 (Reuters) -

* EUROPEAN MEDICINES AGENCY IS SET TO CONSIDER NEXT MONTH WHETHER TO APPROVE PFIZER/BIONTECH VACCINE AND A RIVAL CANDIDATE DEVELOPED BY MODERNA - FT Source text: https://on.ft.com/3le7Gwc Further company coverage:

Latest news about Moderna, Inc.

Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 24	MT
Moderna to Collaborate With OpenAI to Launch New Generation of Medicines	Apr. 24	MT
Moderna: strengthens collaboration with OpenAI	Apr. 24	CF
News Highlights : Top Company News of the Day - Wednesday at 9 AM ET	Apr. 24	DJ
Moderna, Inc. and OpenAI Collaborate to Advance mRNA Medicine	Apr. 24	CI
Pfizer vs Moderna battle over COVID vaccine patents begins in UK	Apr. 23	RE
Alexandria Real Estate's Q1 FFO rises on stronger occupancy rates	Apr. 22	RE
Moderna to deliver 12.5 million Covid vaccines to Brazil	Apr. 22	CF
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 22	MT
Moderna Secures Contract to Supply 12.5 Million COVID-19 Vaccine Doses to Brazil	Apr. 22	MT
Moderna to Supply COVID-19 Vaccines to Brazil	Apr. 22	MT
Moderna, Inc. Announces Contract with Ministry of Health in Brazil to Supply 12.5 Million Covid-19 Vaccines as Part of National Vaccination Campaign	Apr. 22	CI
China's drugmakers can't sell mRNA shots but haven't quit yet	Apr. 19	RE
Moderna Insider Sold Shares Worth $1,575,300, According to a Recent SEC Filing	Apr. 16	MT
Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla...	Apr. 15
Market outlook is uncertain, but optimism prevails	Apr. 15
Redburn Adjusts Moderna's Price Target to $117 From $110	Apr. 12	MT
Moderna pauses Kenya plant plans as COVID vaccine demand wanes	Apr. 11	RE
Moderna Pausing Plan to Build Kenya Vaccine Production Plant	Apr. 11	MT
Moderna Reportedly Pausing Plan to Build Kenya Vaccine Production Plant	Apr. 11	MT
Moderna Reportedly Putting Plan for Kenya Vaccine Plant on Hold	Apr. 11	MT
Moderna puts Kenya plant plans on hold as COVID vaccine demand slumps	Apr. 11	RE
Health Care Down on Retreat From Risk -- Health Care Roundup	Apr. 10	DJ
U.S. stocks inch mostly higher ahead of CPI data	Apr. 09	RE
Health Care Stocks Steady, Moderna Climbs -- Health Care Roundup	Apr. 09	DJ

Chart Moderna, Inc.

Duration

Period

More charts

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am EDT

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm EST

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.2 USD

Average target price

134.3 USD

Spread / Average Target

+26.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+6.77%	40.65B
IQVIA HOLDINGS INC.	+1.12%	42.59B
LONZA GROUP AG	+46.73%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B
BIO-TECHNE CORPORATION	-18.79%	9.85B

Other Biotechnology & Medical Research